Antibe Therapeutics Inc.
ATBPF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Market Cap | $31,044 | $40,312 | $189,518 | $159,082 |
| - Cash | $6,755 | $34,807 | $71,973 | $6,182 |
| + Debt | $0 | $0 | $238 | $2,398 |
| Enterprise Value | $24,289 | $5,505 | $117,783 | $155,298 |
| Revenue | $0 | $0 | $9,713 | $9,666 |
| % Growth | – | -100% | 0.5% | – |
| Gross Profit | $0 | -$99 | $3,550 | $3,696 |
| % Margin | – | – | 36.5% | 38.2% |
| EBITDA | -$19,193 | -$25,148 | -$23,007 | -$17,979 |
| % Margin | – | – | -236.9% | -186% |
| Net Income | -$19,475 | -$25,060 | -$26,301 | -$19,343 |
| % Margin | – | – | -270.8% | -200.1% |
| EPS Diluted | -0.37 | -0.49 | -0.7 | -0.71 |
| % Growth | 24.5% | 30% | 1.4% | – |
| Operating Cash Flow | -$16,305 | -$16,920 | -$105 | -$11,935 |
| Capital Expenditures | -$9 | -$9 | $0 | -$2 |
| Free Cash Flow | -$16,314 | -$16,929 | -$105 | -$11,937 |